Project Grant HT9425261E399
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $560K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $559,999 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on modulating hypoxia-activated stromal programs to potentiate CAR-T cell therapy in kidney cancer. Work is performed in Houston, Texas, with a period of performance through August 31, 2028. The award funds translational oncology research integrating immunotherapy and tumor microenvironment...
- The Defense Health Agency awarded The University of Texas Southwestern Medical Center $1,699,998 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to map, characterize, and elucidate the clinical relevance of driver enhancers in lethal prostate cancer. Work is performed in Dallas, Texas, with a period of performance through June 14, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to...
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $1.248 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel cholesterol-targeting therapies for inflammatory breast cancer. The award funds research and therapeutic development activities through June 30, 2029, performed at MD Anderson's Houston, Texas location. The Military Medical Research and Development program supports basic, applied, and...
- <p>The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $3,466,088 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) for a Technology Therapeutic Development Award.</p> <p>The award funds work performed in Houston, Texas, with a period of performance through August 31, 2029. The source does not specify the products or services to be delivered under this award.</p>
- The Defense Health Agency awarded The University of Texas Southwestern Medical Center $490,000 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research harnessing the unfolded protein response as a therapeutic approach for the treatment of rare choroid plexus carcinoma. The award runs through July 31, 2029, with work performed at UT Southwestern's Dallas, Texas facility. The Military Medical Research and Development program supports...
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $349,976 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research intercepting omental metastasis of ovarian cancer by targeting a mitochondrial redox-IL-10 axis in the immune microenvironment. The award funds basic and applied biomedical research aligned with military medical priorities and spans the period from July 1, 2026, through June 30, 2028. Work is...
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $1,099,986 on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on metabolic rewiring of CAR-T cells to counter the hostile tumor microenvironment in pancreatic cancer. The award funds work performed in Houston, Texas, with a period of performance extending from June 1, 2026, through May 31, 2030. This project grant is classified as assistance funding.
- The Defense Health Agency awarded The Rockefeller University $1.649998 million on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct therapeutic targeting of a commonly inherited breast cancer metastasis driver gene. Work performance is located in New York, NY with a period of performance through July 31, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $1,626,438 on September 15, 2025, for the McCain/Bayh Glioblastoma Consortium under the Military Medical Research and Development program (CFDA 12.420). The award funds research activities under the McCain/Bayh Glioblastoma Consortium. This modification updates the collaborating awards research terms and conditions to reflect a change in the principal investigator for Duke University and updates Division I items....
- The Defense Health Agency awarded The University of Texas Southwestern Medical Center $1,049,994 on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on the therapeutic potential of detecting and inhibiting cytosolic ADP-ribosylation in ovarian cancer. Work is performed in Dallas, Texas, with a period of performance extending from June 1, 2026, through May 31, 2029. The Military Medical Research and Development program supports basic,...